http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
GBT Announces New Employment Inducement Grants
-
GBT Announces Participation at the H.C. Wainwright Global Life Sciences Conference
-
GBT Announces New Employment Inducement Grants
-
GBT Announces Participation at the Cowen and Company 39th Annual Health Care Conference
-
GBT Reports Recent Business Progress and Fourth Quarter and Year-End 2018 Financial Results
-
GBT Announces Participation at the 8th Annual SVB Leerink Global Healthcare Conference
-
GBT Launches ACCEL Grants Program to Improve Access to Care for People with Sickle Cell Disease
-
GBT Announces New Employment Inducement Grants
-
Global Blood Therapeutics (GBT) Reports Publication of Data from Phase 1/2 Study of Voxelotor in Patients with Sickle Cell Disease
-
GBT Announces Publication of Data from Phase 1/2 Study of Voxelotor in Patients with Sickle Cell Disease
-
GBT Announces New Employment Inducement Grants
-
GBT to Present at the 37th Annual J.P. Morgan Healthcare Conference
-
Global Blood Therapeutics (GBT) Appoints Dawn Svoronos to Board of Directors
-
GBT Appoints Dawn Svoronos to Board of Directors
-
GBT Announces New Employment Inducement Grants
-
GBT (GBT) Announces Positive 24-week Results from Phase 3 HOPE Study Demonstrating Statistically Significant Improvements in Hemoglobin and Clinical Measures of Hemolysis
-
GBT Announces Positive 24-week Results from Phase 3 HOPE Study Demonstrating Clinically and Statistically Significant Improvements in Hemoglobin and Clinical Measures of Hemolysis and a Favorable Saf
-
Global Blood Therapeutics (GBT) Announces U.S. FDA Agrees with its Proposal Relating to Accelerated Approval Pathway for Voxelotor for Treatment of SCD and GBT Plans to Submit NDA
-
GBT Announces U.S. FDA Agrees with its Proposal Relating to Accelerated Approval Pathway for Voxelotor for the Treatment of Sickle Cell Disease and GBT Plans to Submit New Drug Application (NDA)
-
GBT to Host Conference Call at 8:30 a.m. Eastern Time Tomorrow to Provide a Regulatory Update for Voxelotor
-
GBT Reports Recent Business Progress and Provides Third Quarter 2018 Financial Results
-
GBT Announces New Employment Inducement Grants
-
GBT Announces Upcoming Data Presentations at 60th American Society of Hematology (ASH) Annual Meeting & Exposition
-
GBT Announces New Employment Inducement Grants
-
GBT Announces Upcoming Presentations at National Sickle Cell Disease Association of America (SCDAA) Convention
-
GBT Announces Participation at the 2018 Cantor Global Healthcare Conference
-
GBT Announces Participation at the 2018 Morgan Stanley Global Healthcare Conference
-
GBT Announces New Employment Inducement Grants
-
GBT Brings Together Sickle Cell Disease Influencers at 7th Annual Sickle Cell Disease (SCD) Therapeutics Conference
-
Global Blood Therapeutics (GBT) Expands SCD Pipeline with Worldwide Licensing Agreement for Inclacumab for the Treatment of Vaso-occlusive Crisis
-
GBT Expands Sickle Cell Disease Pipeline with Worldwide Licensing Agreement for Inclacumab for the Treatment of Vaso-occlusive Crisis
-
GBT Appoints Heidi L. Wagner as Senior Vice President, Government Affairs and Policy
-
GBT Announces Participation at the 2018 Wedbush PacGrow Healthcare Conference
-
GBT Announces New Employment Inducement Grants
-
GBT Reports Recent Business Progress and Provides Second Quarter 2018 Financial Results
-
GBT Announces New Employment Inducement Grants
-
Global Blood Therapeutics (GBT) Reports Statistically Significant Results from Part A of the Phase 3 HOPE Study of Voxelotor
-
GBT Announces Positive Top-line Data from Part A of the Phase 3 HOPE Study of Voxelotor in Sickle Cell Disease
-
Global Blood Therapeutics (GBT) Reports New Phase 2a Voxelotor Data in Adolescents with Sickle Cell Disease
-
GBT Announces New Phase 2a Voxelotor Data in Adolescents with Sickle Cell Disease (SCD) at 23rd European Hematology Association (EHA) Congress
-
Global Blood Therapeutics (GBT) Announces Upcoming Data Presentations Supporting Voxelotor SCD Program
-
GBT Announces Upcoming Data Presentations Supporting Voxelotor Sickle Cell Disease (SCD) Program at Foundation for Sickle Cell Disease Research’s 12th Annual Symposium
-
GBT Announces New Employment Inducement Grants
-
GBT (GBT) Announces Upcoming Data Presentations Supporting Voxelotor Sickle Cell Disease Program at EHA
-
GBT Announces Upcoming Data Presentations Supporting Voxelotor Sickle Cell Disease Program at 23rd European Hematology Association (EHA) Congress
-
GBT Reports Recent Business Progress and First Quarter 2018 Financial Results
-
GBT Announces New Employment Inducement Grants
-
GBT Announces Participation at the H.C. Wainwright Global Life Sciences Conference
-
GBT Announces New Employment Inducement Grants
-
GBT Announces New Employment Inducement Grants

